The revenue beat and positive gross margin are encouraging for the commercial trajectory, but the EPS miss and widening net loss temper enthusiasm. The restructuring plan provides a clearer path to profitability. Watch for continued sales execution and pipeline data readouts (lupus nephritis, pediatric ALL, MS) through 2026-2028. Cash runway into Q4 2027 reduces near-term dilution risk.
Price Chart
Executive Summary
Autolus reported Q1 2026 AUCATZYL net product revenue of $26.2M (vs $9.0M YoY), achieving its first positive gross margin of $1.6M. However, EPS of -$0.27 missed the consensus estimate of -$0.26, and net loss widened to $71.6M. The company reiterated FY2026 revenue guidance of $120-135M and announced a restructuring plan to cut ~$15M in annual operating expenses, including a 13% workforce reduction.
Key Financial Metrics
Key Facts
- Q1 2026 AUCATZYL net product revenue: $26.2M (up 192% YoY from $9.0M)
- First positive gross profit: $1.6M (vs negative gross profit in all prior quarters)
- EPS: -$0.27 vs consensus -$0.26 (miss of 3.8%)
- Net loss: $71.6M vs $70.2M YoY
- Cash, cash equivalents and marketable securities: $229.4M (down from $300.7M at Dec 2025)
- FY2026 revenue guidance reiterated: $120-135M (up from $74M in 2025)
- Restructuring: 13% workforce reduction, ~$15M annualized cost savings from 2027, ~$8M restructuring charges in H1 2026
- Cash runway expected into Q4 2027
Financial Impact
Revenue growth of $17.2M YoY to $26.2M; gross margin turned positive; EPS miss of $0.01; net loss increased by $1.4M
Risk Factors
- Competition from other CAR-T therapies (e.g., Novartis' Kymriah, Bristol-Myers' Breyanzi)
- Execution risk on cost reduction and margin improvement targets
- Clinical trial delays or negative data in pipeline indications
- Potential need for additional financing before reaching profitability
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3294731 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 12, 2026 20d ago | S-3 | $1.94 $1.94 | · 0.00% | ▼ −0.11% | $1.78 (−8.25%) |
Aug 11, 2026 7w ago | 8-K | $2.33 $2.29 | ▼ −1.72% | ▼ −1.31% | $1.78 (−23.61%) |
Aug 3, 2026 8w ago | 8-K | $1.82 $2.07 | ▲ +13.74% | ▲ +11.71% | $1.78 (−2.20%) |
Aug 3, 2026 8w ago | 8-K | $1.82 $2.07 | ▲ +13.74% | ▲ +11.71% | $1.78 (−2.20%) |
Jun 12, 2026 16w ago | Press Release | $1.56 $1.51 | ▼ −3.21% | ▼ −3.88% | $1.78 (+14.10%) |
Jun 11, 2026 16w ago | Institutional Cluster | $1.56 $1.53 | ▲ +1.92% | ▲ +2.36% | $1.78 (−14.10%) |
Jun 9, 2026 16w ago | 8-K | $1.46 $1.50 | ▼ −2.74% | ▼ −0.33% | $1.78 (−21.92%) |
May 21, 2026 19w ago | Press Release | $1.70 $1.84 | ▲ +8.24% | ▲ +6.58% | $1.78 (+4.71%) |
May 14, 2026 20w ago | 8-K | $1.59 $1.65 | ▲ +3.77% | ▲ +4.49% | $1.78 (+11.95%) |
May 14, 2026 20w ago | Press Release | $1.59 $1.65 | ▲ +3.77% | ▲ +4.49% | $1.78 (+11.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access